- Home
- SGN vs KTTA Comparison
SGN vs KTTA Comparison
Compare SGN & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- KTTA
- Stock Information
- Founded
- SGN 2019
- KTTA 2020
- Country
- SGN United States
- KTTA United States
- Employees
- SGN N/A
- KTTA N/A
- Industry
- SGN
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- SGN
- KTTA Health Care
- Exchange
- SGN Nasdaq
- KTTA Nasdaq
- Market Cap
- SGN 4.1M
- KTTA 3.5M
- IPO Year
- SGN 2023
- KTTA 2021
- Fundamental
- Price
- SGN $0.18
- KTTA $3.38
- Analyst Decision
- SGN
- KTTA
- Analyst Count
- SGN 0
- KTTA 0
- Target Price
- SGN N/A
- KTTA N/A
- AVG Volume (30 Days)
- SGN 4.9M
- KTTA 29.8K
- Earning Date
- SGN 11-25-2024
- KTTA 11-13-2024
- Dividend Yield
- SGN N/A
- KTTA N/A
- EPS Growth
- SGN N/A
- KTTA N/A
- EPS
- SGN N/A
- KTTA N/A
- Revenue
- SGN $576,488.00
- KTTA N/A
- Revenue This Year
- SGN N/A
- KTTA N/A
- Revenue Next Year
- SGN N/A
- KTTA N/A
- P/E Ratio
- SGN N/A
- KTTA N/A
- Revenue Growth
- SGN 218.74
- KTTA N/A
- 52 Week Low
- SGN $0.11
- KTTA $3.19
- 52 Week High
- SGN $2.70
- KTTA $17.40
- Technical
- Relative Strength Index (RSI)
- SGN 42.04
- KTTA 38.62
- Support Level
- SGN $0.18
- KTTA $3.20
- Resistance Level
- SGN $0.29
- KTTA $3.46
- Average True Range (ATR)
- SGN 0.03
- KTTA 0.35
- MACD
- SGN -0.00
- KTTA -0.01
- Stochastic Oscillator
- SGN 18.66
- KTTA 16.38
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.